Literature DB >> 11040277

Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.

A Di Bacco1, K Keeshan, S L McKenna, T G Cotter.   

Abstract

Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, characterized by the presence of the Bcr-Abl oncoprotein. The main characteristics of this disease include adhesion independence, growth factor independence, and resistance to apoptosis. Loss or mutation of the tumor suppressor gene, p53, is one of the most frequent secondary mutations in CML blast crisis. The transition between chronic phase and blast crisis is associated with increased resistance to apoptosis correlating with poor prognosis. This review focuses on the involvement of these two oncoproteins in the development and progression of the apoptotic-resistant phenotype in CML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040277     DOI: 10.1634/theoncologist.5-5-405

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  12 in total

1.  Multiple constitutional chromosome translocations of familial nature in Philadelphia chromosome-positive chronic myeloid leukemia: a report on a unique case.

Authors:  Béla Kajtár; Linda Deák; Veronika Kalász; László Pajor; Lenke Molnár; Gábor Méhes
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

Review 2.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

3.  Automated identification of abnormal metaphase chromosome cells for the detection of chronic myeloid leukemia using microscopic images.

Authors:  Xingwei Wang; Bin Zheng; Shibo Li; John J Mulvihill; Xiaodong Chen; Hong Liu
Journal:  J Biomed Opt       Date:  2010 Jul-Aug       Impact factor: 3.170

4.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

5.  Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.

Authors:  Jason G Harb; Brenda I Chyla; Claudia S Huettner
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Authors:  Jean-Claude Chomel; Ali G Turhan
Journal:  Oncotarget       Date:  2011-09

Review 7.  Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?

Authors:  Vivian M Rumjanek; Raphael S Vidal; Raquel C Maia
Journal:  Biosci Rep       Date:  2013-11-25       Impact factor: 3.840

8.  The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.

Authors:  Kevin R Kelly; Jeffrey Ecsedy; Ernest Medina; Devalingam Mahalingam; Swaminathan Padmanabhan; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

9.  Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia.

Authors:  Xiaomei Chen; Wei Xiong; Huiyu Li
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

10.  Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Authors:  G Heller; T Topakian; C Altenberger; S Cerny-Reiterer; S Herndlhofer; B Ziegler; P Datlinger; K Byrgazov; C Bock; C Mannhalter; G Hörmann; W R Sperr; T Lion; C C Zielinski; P Valent; S Zöchbauer-Müller
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.